Fibrocell Science, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2015-11-05: Form 8-K; Period of report 2015-11-05; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2015-09-25: Form 8-K; Period of report 2015-09-25; Description 8.01 Other Events; Details 8.01.
- 2015-09-16: Form 8-K; Period of report 2015-09-14; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2015-09-08: Form 8-K; Period of report 2015-09-03; Description 4.01 Changes in Registrant's Certifying Accountant; Details 4.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2015-11-05 | 8-K | 2015-11-05 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On November 5, 2015, Fibrocell Science, Inc. ("Fibrocell") issued a press release announcing its financial results for the three and nine months ended September 30, 2015. 7.01 On November 5, 2015, Fibrocell posted an updated Corporate Presentation on its website (www.fibrocell.com). | fcsc110515form8-kfor3q15ea.htm |
| 2015-09-25 | 8-K | 2015-09-25 | 8.01 Other Events | 8.01 On September 25, 2015, Fibrocell Science, Inc. issued a press release to provide a regulatory update for its product candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). | fcsc092515form8-k.htm |
| 2015-09-16 | 8-K | 2015-09-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On September 14, 2015, the Company entered into an Employment Agreement with John Maslowski in connection with Mr. Maslowski's promotion from Vice President of Scientific Affairs to Senior Vice President of Scientific Affairs. | fcsc091415form8-k.htm |
| 2015-09-08 | 8-K | 2015-09-03 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On September 3, 2015, Fibrocell Science, Inc. (the “Company”) dismissed BDO USA, LLP (“BDO”) as its independent registered public accounting firm. | fcsc090315form-8k.htm |
| 2015-08-06 | 8-K | 2015-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2015, Fibrocell Science, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2015. | fcsc080615form8kfor2q15ear.htm |
| 2015-07-27 | 8-K | 2015-07-27 | 8.01 Other Events | 8.01 On July 27, 2015, Fibrocell Science, Inc. (“Fibrocell”) consummated its previously announced underwritten offering (the “Offering”) of Fibrocell’s common stock, par value $0.001 per share (the "Common Stock"), which Offering is more fully described in Fibrocell’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2015. | fcsc072715form8-kforclosin.htm |
| 2015-07-22 | 8-K | 2015-07-22 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 - Entry into a Material Definitive Agreement. 8.01 On July 22, 2015, Fibrocell issued a press release announcing the pricing of the Offering. | fcsc072215form8kforpropose.htm |
| 2015-07-21 | 8-K | 2015-07-21 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 – Results of Operations and Financial Condition. 8.01 On July 21, 2015, Fibrocell issued a press release announcing the commencement of a firm commitment underwritten public offering. | fcsc072115form8kforprelimi.htm |
| 2015-07-20 | 8-K | 2015-07-20 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 – Regulation FD Disclosure. 8.01 On July 20, 2015, Fibrocell submitted an IND with the U.S. Food and Drug Administration ("FDA") for FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa ("RDEB"). | fcsc072015form8kforindfili.htm |
| 2015-06-24 | 8-K | 2015-06-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On June 24, 2015, Fibrocell Science, Inc. (the "Company ") held its Annual Meeting of Stockholders (the "Annual Meeting") at the Hilton Garden Inn, 720 Eagleview Blvd., Exton, Pennsylvania. | fcsc062415form8kforasm.htm |
| 2015-06-08 | 8-K | 2015-06-08 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 – Regulation FD Disclosure. 8.01 On June 8, 2015, Fibrocell announced positive in vitro pre-clinical data for Fibrocell’s lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa. | fcsc060815form8kforeshgrel.htm |
| 2015-05-12 | 8-K | 2015-05-12 | 8.01 Other Events | 8.01 On May 12, 2015, Fibrocell Science, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has granted rare pediatric disease designation for the Company’s lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa. | a15-11457_18k.htm |
| 2015-05-08 | 8-K | 2015-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2015, Fibrocell Science, Inc. issued a press release announcing the financial and operating results for the quarter ended March 31, 2015. | form8-k_1q2015earningsrele.htm |
| 2015-05-01 | 8-K | 2015-04-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 30, 2015, Robert Sheroff, our Vice President, Technical Operations and one of our named executive officers, informed Fibrocell Science, Inc. (the “Company”) of his decision to resign effective June 1, 2015. | form8-kmay12015.htm |
| 2015-04-21 | 8-K | 2015-04-20 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure | 5.03 On April 20, 2015, the Board of Directors of Fibrocell Science, Inc. (the “Company”) adopted an amendment to the Fourth Amended and Restated Bylaws of the Company (the “Bylaws Amendment”). 7.01 On April 21, 2015, the Company posted the presentation attached as exhibit 99.1 on its web site www.fibrocellscience.com. | form8-kapril212015corpdeck.htm |
| 2015-03-18 | 8-K | 2015-03-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 18, 2015, Fibrocell Science, Inc. (the “Company”) announced the appointment of Keith A. Goldan as Chief Financial Officer, Senior Vice President, Treasurer and Corporate Secretary of the Company, effective immediately. | form8k_employmentagr.htm |
| 2015-03-13 | 8-K | 2015-03-13 | 2.02 Results of Operations and Financial Condition | 2.02 On March 13, 2015, Fibrocell Science, Inc. issued a press release announcing the financial and operating results for its fourth quarter and full year ended December 31, 2014. | a8-kpressrelease2014fullxy.htm |
| 2015-01-12 | 8-K | 2015-01-12 | 7.01 Regulation FD Disclosure | 7.01 Fibrocell Science, Inc. (the “Company”) is using the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K in conjunction with its presentation at the Biotech Showcase 2015 Conference held on January 12, 2015 in San Francisco, California. | form8-kfiliing1x12x15.htm |